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Abstract
The steroid hormone aldosterone is a key regulator of electrolyte trans-
port in the kidney and contributes to both homeostatic whole-body
electrolyte balance and the development of renal and cardiovascular
pathologies. Aldosterone exerts its actionprincipally through theminer-
alocorticoid receptor (MR), which acts as a ligand-dependent transcrip-
tion factor in target tissues. Aldosterone also stimulates the activation of
protein kinases and secondary messenger signaling cascades that act in-
dependently on speciﬁcmolecular targets in the cell membrane and also
modulate the transcriptional action of aldosterone through MR. This
review describes current knowledge regarding the mechanisms and tar-
gets of rapid aldosterone action in the nephron and how aldosterone
integrates these responses into the regulation of renal physiology.
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MR:
mineralocorticoid
receptor, i.e., nuclear
receptor NR3C2
RAAS: renin-
angiotensin-
aldosterone
system
INTRODUCTION
Almost 60 years ago, the corticosteroid
hormone aldosterone was isolated, and its
physiological effects on renal function were
identiﬁed (1). Since then, there have been
many important milestones in the evolution of
our understanding of the mechanisms under-
pinning aldosterone action: the identiﬁcation
of the mineralocorticoid receptor (MR) as the
principal aldosterone receptor (2); the charac-
terization of aldosterone functional targets such
as the epithelial Na+ channel (ENaC), the renal
outer medullary K+ channel (ROMK), and the
serum- and glucocorticoid-regulated kinase
(SGK); and the elucidation of many of the
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Figure 1
The modulation of membrane transporters by aldosterone-induced signaling intermediates. Aldosterone
treatment modulates the activity of key signaling intermediates such as Rho-activated kinase (ROK), protein
kinase D (PKD), protein kinase A (PKA), phosphoinositide 3-kinase (PI3K), protein kinase C (PKC),
extracellular stimulus–regulated kinase (ERK), serum- and glucocorticoid-activated kinase (SGK), and the
with no lysine family kinases (WNKs) to modulate the activity of the epithelial Na+ channel (ENaC), the
renal outer medullary K+ channel (ROMK), ATP-sensitive K+ channels (KATP), Na+/hydrogen exchanger
1 (NHE1), and the Na+/K+ pump (Na+/K+-ATPase) in the principal cells of the collecting duct. In the
intercalated cells, aldosterone rapidly stimulates H+ secretion via H+-ATPase through PKC-dependent
trafﬁcking of the proton pump into the apical membrane. Aldosterone also modulates large-conductance K+
(BK) channel activity and shifts kidney anion exchanger (kAE) activity from the basolateral membrane to the
apical membrane.
processes that couple the receptor and effectors
to achieve the physiological responses (3–6)
(Figure 1). Aldosterone is released from
the adrenal gland in response to two very
distinct physiological stimuli: either (a) the
production of angiotensin II through the
renin-angiotensin-aldosterone system (RAAS),
which occurs under conditions of hypotension,
or (b) an elevated plasma K+ concentration,
which causes membrane depolarization of
aldosterone-secreting cells (7–9). The nature
of these stimuli deﬁnes the ultimate physio-
logical effects of aldosterone release, which
are either to elevate blood pressure through
changes in vascular tone and electrolyte trans-
port across absorptive epithelia or to promote
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PHA: pseudohypoal-
dosteronism
Rapid responses to
steroid hormones:
signaling or
physiological
responses initiated by
steroid hormones in
target tissues that do
not require changes in
gene expression
mediated by the
transcriptional effects
of their nuclear
receptors
the secretion of excess K+ from the body under
conditions of hyperkalemia.
The consequences of dysregulation of
the physiology of aldosterone release, MR
function, and their physiological targets are
manifested in the contribution of such defects
to rare genetic disorders such as pseudohy-
poaldosteronism type I (PHAI), in which MR
is mutated (10), or PHAII, in which the key
transporter regulators, WNK (with no lysine
kinase) types 1 and 4 (WNK1 and WNK4), are
mutated (11). These disorders have provided
important information about aldosterone ac-
tion and have helped to identify targets within
the RAAS cascade for therapeutic intervention
in chronic hypertension and the control of its
adverse cardiovascular effects. The renal and
cardiovascular systems are the key targets of
aldosterone action, with impacts on electrolyte
balance and blood pressure, but aldosterone
also exerts its effects in the respiratory and
digestive tracts, where MR is expressed, and
in the brain (12). The kidney is the principal
site for Na+ conservation and the maintenance
of K+ homeostasis in the body. The cells of
the distal nephron adapt their responses to the
two different stimuli that promote aldosterone
release through the interaction of aldosterone-
induced responses with other components of
the RAAS, in particular coincident angiotensin
II–induced responses that are activated only
under conditions of hypotension (13, 14).
To date, MR is the only known speciﬁc re-
ceptor for aldosterone. However, aldosterone
can bind to the glucocorticoid receptor (GR)
with low afﬁnity (15). Moreover, the existence
of a high-afﬁnity membrane-associated recep-
tor that is insensitive to MR antagonism and
is unable to bind glucocorticoids has been de-
tected in the vascular endothelium (16). The
identity of this putative aldosterone mem-
brane receptor has not been established, al-
though supportive evidence for its existence
comes from several sources. A 50-kDa pro-
tein with high aldosterone-binding afﬁnity was
isolated from human lymphocytes; unlike MR,
this protein does not bind cortisol (17). In ad-
dition, aldosterone-induced rapid cyclic AMP
(cAMP) and intracellular Ca2+ concentration
[Ca2+]i responses were detected in cells iso-
lated from MR knockout mice (18). In com-
mon with other steroid nuclear receptors, MR
is a ligand-activated transcription factor. The
binding of aldosterone stabilizes the interac-
tion of MR with speciﬁc DNA sequence ele-
ments in the promoter regions of aldosterone-
responsive genes to promote or suppress their
expression through the recruitment of speciﬁc
coactivators or corepressors (2). Aldosterone-
bound MR binds to DNA-regulatory elements
that are also recognized by GR. Consequently,
heterodimerization as well as homodimeriza-
tion of these receptors can occur at complete
palindromic glucocorticoid response element
(GRE) sites, adding a further level of integra-
tion to the regulation of gene expression by al-
dosterone and glucocorticoids. The transcrip-
tional effects stimulated by aldosterone through
MR are augmented by the rapid activation of
signal transduction cascades, which aremost of-
ten initiated through the interaction of aldos-
terone with MR. Even though some of these
rapid signaling responses have been known for
some time, it is only recently that their rele-
vance to the physiological effects of aldosterone
has been characterized and their synergismwith
the transcriptional responses to aldosterone has
been established.
The expression of MR identiﬁes
aldosterone-sensitive tissues, including the vas-
cular endothelium, cardiac myocytes, and the
epithelium of the colon and the renal tubule.
The nephron is the principal site for Na+ con-
servation and K+ secretion, and these critical
processes are under precise hormonal control
to maintain electrolyte homeostasis. The
aldosterone-sensitive distal nephron (ASDN),
comprising the distal convoluted tubule, the
connecting tubule, and the collecting duct,
expresses MR, and within the collecting
duct, the principal cells express signiﬁcantly
more MR than do the intercalated cells (19).
The principal and intercalated cell types
express distinct subsets of transporters and
channels. The transporters expressed by the
MR-expressing epithelial cells of the nephron,
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ASDN: aldosterone-
sensitive distal
nephron
such as ENaC, ROMK, the Na+/K+ pump,
and Na+/H+ exchanger (NHE) isoforms, are
all subject to regulation by aldosterone. This
regulation is achieved through the modulation
of transporter subunit expression, as in the
case of the ENaCα subunit, or through
the transcriptional modulation of regulatory
proteins such as SGK1 (3, 20, 21). SGK1
is constitutively active, and unlike the other
SGK isoforms, its expression is induced by
aldosterone to modulate the activities of ENaC
and ROMK. This is achieved either through
the inhibition of channel ubiquitination or
through interaction with the WNK family
(14, 22). Acutely activated protein kinases and
secondary messengers are also key regulators
of transporter and ion channel activity, either
directly through the modulation of site-speciﬁc
subunit phosphorylation or indirectly through
the stimulation of subcellular trafﬁcking, to
affect the abundance of these proteins in
the cell membrane. The modulation of key
transport proteins located in the ASDN by the
signaling cascades that are rapidly activated by
aldosterone is the subject of this review.
THE COUPLING OF
MINERALOCORTICOID
RECEPTOR TO GROWTH
FACTOR RECEPTORS
The interaction between aldosterone and MR
initiates rapidly activated signaling cascades
that can be blocked using speciﬁc MR antag-
onists such as spironolactone and eplerenone.
The capacity to display rapid aldosterone ac-
tions can be conferred on MR-null cells by
exogenous expression of the receptor (23),
and these signaling events can be initiated
by expressing recombinant MR that lacks
the coactivator-binding and DNA-binding do-
mains (24). Some actions of aldosterone in renal
cells cannot be conferred through MR expres-
sion or antagonized by spironolactone pretreat-
ment; these include the transient rise in [Ca2+]i
(23). These data have been interpreted in dif-
ferent ways as evidence either that a completely
novel, structurally distinct receptor initiates the
nongenomic signal or that MR assumes dif-
ferent tertiary conformations that reconﬁgures
the structure of its ligand-binding domain. The
ligand-receptor conformation adopted may de-
pend on the identity of theMR-interacting pro-
teins, which in turn affect MR sensitivity to a
particular antagonist. Evidence also points to
aldosterone-binding sites on the membranes of
renal cells (25, 26), which again either sug-
gests that a small subset of expressed MR is
associated with the cell membrane or points
to the existence of a distinct membrane re-
ceptor for aldosterone. There is no physico-
chemical evidence for a transmembrane domain
in any steroid nuclear receptor, and because
MR lacks the palmitoylation site proposed for
the membrane estrogen receptor, MR most
likely associates transiently with the membrane
through its interaction with another protein (as
yet unidentiﬁed) that is more stably tethered at
the cell membrane. Such an interactionmay re-
sult in a MR conformation that is less spirono-
lactone sensitive. It has further been proposed
that spironolactone-insensitive effects of aldos-
terone can be effectively blocked using the MR
antagonist eplerenone due to the more ﬂexible
structure of this compound (27).
The intermediate steps coupling the
aldosterone-MR interaction to the rapid
nongenomic activation of speciﬁc protein
kinases are not fully characterized. However,
the transactivation of the epidermal growth
factor receptor (EGFR) is a crucial step in
transducing this activating signal to the various
downstream signaling intermediates that are
responsive to aldosterone (28). The molecular
mechanism by which EGFR activation is
coupled to MR is still unclear and appears to
be EGFR ligand independent. An activation
model that is akin to the transactivation of
EGFR by the estrogen receptor and is based on
the matrix metalloproteinase cascade and the
liberation of heparin-bound EGF cannot be
ruled out (29, 30). c-Src phosphorylates EGFR
within 5 min of aldosterone treatment. The ac-
tivation of c-Src is one of the earliest signaling
responses promoted by aldosterone in renal
cells and identiﬁes this small tyrosine kinase as
5.4 Thomas · Harvey
PH73CH05-Harvey ARI 30 August 2010 21:5
a key intermediate signal (31). MR resides in a
complex with other proteins such as heat shock
protein 90 (Hsp90) prior to ligand binding
and nuclear shuttling. Antagonism of Hsp90
protein interactions using the geldanamycin
analog 17-AAG blocks the c-Src-dependent
phosphorylation of EGFR at Tyr845 and also
suppresses EGFR-dependent downstream
signaling events following aldosterone treat-
ment (31, 32). Aldosterone-induced signaling
events that are coupled to EGFR include the
activation of extracellular stimulus–regulated
kinase (ERK)1/2,MAP kinase (28), and protein
kinase D (PKD) (32).
Phosphoinositide 3-kinase (PI3K) is a key
regulator of aldosterone action andwas believed
to be the point of signaling convergence with
insulin-induced effects in the nephron (33).
SGK1 is activated in HEK 293 cells follow-
ing insulin treatment through phosphorylation
of SGK1 at residues Thr256 and Ser422, and
insulin-induced SGK1 activation is stimulated
within 2 min through PI3K-dependent activa-
tion of 3-phosphoinositide-dependent kinase 1
(PDK1) (34). Aldosterone treatment stimulates
PI3K activity to promote Akt activation within
10 min of treatment in A6 cells through a path-
way dependent on transactivation of insulin-
like growth factor receptor-1β (IGF-R1β) (35).
In this experimental system, aldosterone stim-
ulated, within 1 h of treatment, a two- to three-
fold increase in the transepithelial, amiloride-
sensitive current, which was blocked by PI3K
antagonism. PDK1 can activate PKD via the
activation of novel protein kinase C (PKC) iso-
forms such as PKCδ or PKCε (36); such acti-
vation may point to further synergy between
aldosterone and insulin-induced signaling
responses.
REGULATION OF ENaC
STABILITY BY ALDOSTERONE
The epithelial Na+ channel ENaC is a major
effector of aldosterone. Fully active ENaC—a
heterotrimeric channel complex composed
of one α subunit, one β subunit, and one γ
subunit—localizes to the apical membrane of
the principal cells of the distal nephron and
other absorptive epithelia (37, 38). ENaC
surface abundance and open probability de-
termine the rate of Na+ reabsorption from
the renal ultraﬁltrate across the epithelium.
Consequently, ENaC activity is a key regulator
of aldosterone-mediated Na+ conservation by
the kidney. ENaC continually cycles between
the cell membrane and a subapical, intracellular
pool (39). ENaC can also be ubiquitinated
by Nedd4-2 ubiquitin ligase and directed
for degradation by the proteasome (40).
Thus, equilibrium exists between the various
processes that contribute to ENaC subunit
transcriptional regulation, subcellular trafﬁck-
ing, and expressed protein stability to achieve a
steady state in ENaC surface expression. Any of
these regulatory steps can be acted upon acutely
or chronically to modulate the rate of Na+ re-
absorption in the nephron. The transcriptional
regulation of SGK1 is the principal mechanism
by which aldosterone modulates ENaC activity
through a regulatory kinase (3, 41). The phos-
phorylation of Nedd4-2 by SGK1 suppresses
its capacity to bind to the COOH-terminal PY
motifs of ENaCβ and ENaCγ, suppressing
their ubiquitination and promoting the stabil-
ity of these ENaC subunits in the apical cell
membrane (42, 43). Nedd4-2 is also a substrate
for phosphorylation at its SGK1 target residue,
Ser444, by PKA (42) and the inhibitor of κB
kinase (IKK) β isoform (44). ENaC subunit
stability is further enhanced by the tran-
scriptional upregulation of ubiquitin-speciﬁc
proteinase 2-45 (USP2-45) by aldosterone,
which deubiquitinates ENaC subunits and res-
cues the channel from proteolysis (45). Studies
using SGK1 knockout mice show differences
in the scale of the SGK1 contribution to pro-
moting ENaC activity. Generally, these mice
display only a mild salt-wasting phenotype
compared with MR and ENaCα knockouts,
even under conditions of salt restriction (46,
47), suggesting that the action of SGK1 on
channel stability can only partly account for
the activation of ENaC by aldosterone.
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RAPID REGULATION
OF ENaC TRAFFICKING
BY ALDOSTERONE
Recent studies have identiﬁed novel signaling
pathways that modulate ENaC activity by al-
tering the subcellular trafﬁcking of the channel
and so can reﬁne the transcriptional effects
exerted by aldosterone on ENaCα and SGK1
expression. The Rho subfamily of the Ras small
GTPases has been implicated in the regulation
of ENaC through the activation of associated
kinases that regulate cytoskeletal organization
and also inﬂuence phosphoinositide signaling.
In various tissues, aldosterone activates cas-
cades coupled to the Ras superfamily of small
GTPases. These molecular switches have a
signiﬁcant impact on physiological responses to
aldosterone. For example, aldosterone induces
both the expression and activation of K-Ras in
renal cells, which, through stimulation of PI3K,
promotes ENaC open probability (48). A con-
stitutively active form of one of the Rho small
GTPases, Rac1, ampliﬁes aldosterone-induced
gene expression and stabilizes the association
of MR with the nucleus following aldosterone
treatment (49). In mesangial cells, aldosterone
promotes the activation of Rho kinase (ROK),
which is coupled to RhoA activation within
10 min of treatment (50). The activation of
ROK is required for aldosterone-induced my-
oﬁbroblastic transdifferentiation of these cells,
which is associated with changes in the protein
expression proﬁle and with the stimulation
of cell hypertrophy. The activation of ROK
contributes to both the promotion of cardiac
ﬁbrosis (51) and the exacerbation of renal is-
chemia (52) by aldosterone. These pathological
states aremarked by the aldosterone-dependent
generation of reactive oxygen species, which
synergize with ROK activation to inﬂict tissue
damage.
Classically, the activation of different Rho
GTPases and their associated kinases is as-
sociated with changes in the structural con-
ﬁgurations of cytoplasmic actin and conse-
quently impacts subcellular vesicle trafﬁcking.
Dynein motor–dependent vesicle trafﬁcking
relies on actin polymerization and bundling,
and cytoskeletal structures also tether cell-
surface ENaC within discrete domains at
the apical membrane (53). The activity of
phosphatidylinositol-4-phosphate 5-kinase, a
type II phosphatidylinositol phosphate (PIP)
kinase, is also coupled to RhoA activation
and regulates Golgi ﬁssion to release ENaC-
containing transport vesicles (54). The serine/
threonine kinase PKD1 also regulates type II
PIP kinases (55). The three members of the
PKD family of protein kinases, implicated in
a wide range of physiological processes, play a
pivotal role in the maintenance of Golgi struc-
ture and post-Golgi vesicle trafﬁcking (56, 57).
PKD1 activation in response to aldosterone
affects the subcellular distribution of preex-
pressed ENaC subunits in renal collecting duct
cells within 5 min of hormone treatment; how-
ever, increased apical membrane insertion of
ENaC is not observed until after 60 min (58).
The activation of PKD1 by aldosterone not
only may determine the rate of aldosterone-
induced ENaC subunit trafﬁcking to the apical
membrane butmay also have amore general ef-
fect on subcellular trafﬁcking of proteins in the
cells of the distal nephron.
Aldosterone transcriptionally upregulates
the expression of the 17-kDa glucocorticoid-
induced leucine zipper protein (GILZ) in re-
nal cortical collecting duct cells (59), where
it suppresses basal ERK1/2 activation to pro-
mote the increased surface expression of ENaC
and consequently stimulates Na+ reabsorption
(60). GILZwas ﬁrst identiﬁed in the kidney but
has been most intensively studied in the con-
text of its role in the anti-inﬂammatory effects
of glucocorticoids on cells of the immune sys-
tem through its interaction with Ras and nu-
clear factor κB (NFκB) (reviewed in Reference
61). Multiple isoforms of GILZ are expressed
in the kidney and have distinct biological roles,
including the modulation of ENaC trafﬁcking
and the suppression of cell proliferation (62).
In renal cell lines, GILZ1 stimulates the ENaC
Na+ current, whereas GILZ2 and GILZ3 also
promote channel trafﬁcking to the apical mem-
brane without a concurrent rise in ENaC
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CCD: cortical
collecting duct
TAL: thick ascending
limb of the loop of
Henle
activity. GILZ1 and GILZ3 effectively inhibit
ERK1/2phosphorylation,whereasGILZ4 sup-
presses cell proliferation but promotes ERK1/2
phosphorylation. GILZ binds to activated Ras
to suppress ERK1/2 and Akt activation (63) and
binds to Raf to block only the ERK1/2 path-
way (63). Different amino acid residues are in-
volved in each of these interactions, and con-
sequently GILZ can also form heterotrimeric
complexes with Ras and Raf. GILZ has poten-
tial phosphorylation sites that may determine
its molecular interactions; however, the kinases
that determine GILZ isoform phosphorylation
states are yet to be determined. The charac-
terization of these signaling intermediates will
be important because it will help to discern
why aldosterone appears to have differing ef-
fects on Ras-coupled signaling in the context
of the upregulation of K-Ras expression and
the simultaneous suppression of interactions of
Raswith downstreameffectors likeERK1/2 and
Akt.
The explanation for aldosterone activation
of antagonistic signaling events probably lies in
the subcellular localization of signaling inter-
mediates that regulate particular transporters to
discrete complexes, although the same signal-
ing intermediates may also be localized to other
complexes that are differentially regulated (64).
Nedd4-2 resides in an inhibitory complex with
SGK1,Raf-1, andGILZ1 that is associatedwith
ENaCβ (65). Increased expression of SGK1
and GILZ suppresses Raf-1 and Nedd4-2 ac-
tivity in this complex and promotes ENaC traf-
ﬁcking to the membrane by suppressing chan-
nel ubiquitination. The effects of heterologous
expression of SGK1 and GILZ on this protein
complex can be replicated in polarized corti-
cal collecting duct (CCD) cells by aldosterone
treatment for 4 h. PKD is activated in response
to aldosterone treatment of CCD cells, and
the interaction of PKD with ERK1/2, PKCδ,
and PKCε is altered following activation, illus-
trating a change in the complement of a fur-
ther multicomponent signaling complex linked
to the Raf–MAP/ERK kinase (MEK)–ERK
cascade (58, 66).
RAPID MODULATION
OF Na+/K+-ATPASE
BY ALDOSTERONE
The circulatory K+ concentration is precisely
regulated to maintain efﬁcient functioning of
excitable cells. The kidney contributes to K+
homeostasis through K+ reabsorption from the
renal ultraﬁltrate passing through the proxi-
mal tubule and the thick ascending limb of
the loop of Henle (TAL). Hormone-regulated
K+ excretion is maximal in the principal cells
of the ASDN. The activity of the Na+/K+-
ATPase provides the electrochemical driving
force for aldosterone-induced apical Na+ re-
absorption through ENaC (67). This pro-
vides a favorable electrochemical gradient for
K+ transported into the cytoplasm to be se-
creted across the apical membrane into the
ultraﬁltrate through K+ channels, principally
ROMK (Kir1.1), or alternatively recycled back
into the blood through basolateral K+ chan-
nels. The route taken by K+ is determined by
other aldosterone-regulated K+ channels and
the concurrent activation of transporters reg-
ulated by angiotensin under conditions of hy-
potension. There are contradictory reports in
the literature going back to the early 1980s
as to whether aldosterone can acutely affect
Na+/K+-ATPase activity in adrenalectomized
animals (68–70). The discrepancies may be due
to differences in the time of adrenalectomy
and so to the period of aldosterone depletion
prior to experimentation (71). Under condi-
tions in which ENaC activity was blocked or
Na+ was absent from bath solutions, aldos-
terone still stimulated Na+/K+-ATPase activ-
ity within 30 min of treatment (71). Na+/K+-
ATPase activity is also sensitive to intracellular
pH, which affects the cation-binding speciﬁcity
of the pump (72, 73). Transient activation of
NHE1 is one of the earliest physiological re-
sponses observed in aldosterone-treated CCD
cells (74–76) and may contribute to the earli-
est phase of Na+/K+-ATPase modulation by
aldosterone.
Aldosterone induction of Na+/K+-ATPase
activity is at least biphasic; the initial phase
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occurs in advance of detectable increases in
α-subunit expression 6 h after aldosterone
treatment (77). The later phase results in the
accumulation of a Na+/K+-ATPase pool that
can be recruited to the basolateral membrane
in response to agonists such as vasopressin (78,
79). Aldosterone can also induce a very rapid
translocation (<1 h) of α-Na+/K+-ATPase
into the cell membrane with a concurrent rise
in pump current that is maximal after 2 h in
a colon cell line (80). Here a signiﬁcant rise
in SGK1 activity was measurable after aldos-
terone treatment for 1 h; however, there was a
twofold rise in PI3K activity within 30 min of
aldosterone treatment. PI3K is an important
regulator of Na+/K+-ATPase trafﬁcking and
regulates incorporation of the pump into
endosomes. The p85 subunit of PI3K directly
binds the proline-rich motif of α-Na+/K+-
ATPase when the pump subunit has undergone
PKC-dependent phosphorylation at residues
Ser11 and Ser18 (81). Aldosterone treatment
of CCD cells results in the rapid activation of
multiple PKC isoforms: PKCα (82), PKCδ,
and PKCε (58). PKCε activation suppresses
pump current in cardiac myocytes (83). There
are four isoforms of α-Na+/K+-ATPase.
Isoform α1 is ubiquitous in its expression and
is the isoform regulated by aldosterone in the
nephron; α2 is expressed in the brain, skeletal
muscle, and cardiac myocytes, and α3 and α4
are expressed in the brain and testis, respec-
tively (84). Structural differences between the
α-Na+/K+-ATPase isoforms contribute to
differences in their mechanism of regulation.
For example, α1 and α3 differ at sequences
proximal to the ATP-binding site so that α1
is activated by PKC whereas α3 is not (85).
Ca2+-dependent isoforms PKCα and PKCβ
mediate the phosphorylation of α-Na+/K+-
ATPase at its proline-rich motif (86), whereas
PKA-dependent phosphorylation occurs at
Ser943. The PKA phosphorylation event has
variously been linked to the promotion (87) and
inhibition (88) of pump activity in response to
different agonists. The most likely explanation
is that the acute regulation of pump activity
through direct phosphorylation and trafﬁcking
represents the summation of multiple signaling
cascades. The ﬁnding that intracellular Na+
concentration ([Na+]i) can affect pump surface
recruitment through the cAMP-independent
stimulation of PKA (89) raises the question
of whether aldosterone-induced NHE activity
can activate the pump. This ﬁnding also high-
lights the importance of Na+ self-inhibition of
ENaC to stop an uncontrolled rise in [Na+]i
when ultraﬁltrate Na+ concentration is high.
RAPID EFFECTS OF
ALDOSTERONE ON
INTERCALATED CELL
H+-ATPASE
The major mechanism of tubular acidiﬁcation
in the CCD involves active, electrogenic H+
secretion through vacuolar-type H+-ATPase
pumps located in intercalated α-type cells. It
has been known since the early 1990s that corti-
costeroids can enhance late distal tubule acid se-
cretion (90). Aldosterone acts on H+ transport
in CCD cells, resulting in rapid nongenomic
activation of H+-ATPase pumps (91), H+ con-
ductance (92), andNa+/H+ exchange (74). The
molecular mechanisms of rapid nongenomic
actions of aldosterone on the various acid ex-
trusion transporters and the consequences for
whole-body acid-base balance and the regula-
tion of pH-sensitive ion transporters and sig-
naling enzymes are still largely unknown and
provide a ripe area for future research. The ear-
liest reports of aldosterone stimulation of the
vacuolar-type H+-ATPase pump came from
studies in amphibian skin and urinary bladder,
which revealed a rapid action of the hormone
on proton ﬂux through H+-ATPase pumps
in mitochondria-rich intercalated cells (93).
These early studies showed that aldosterone
stimulated H+ secretion independently of Na+
transport as a result of trafﬁcking of proton
pumps stored in cytosolic vesicles into the api-
cal membrane of intercalated cells via a PKC-
dependent signaling pathway (94).Morpholog-
ical changes in intercalated cell number and
apical membrane area were also found to be a
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feature of long-term exposure to aldosterone or
deoxycorticosterone (95).
In Madin-Darby canine kidney (MDCK)
cells, both aldosterone and vasopressin activate
a baﬁlomycin-sensitive proton ﬂux (vacuo-
lar H+-ATPase) acting separately through
MR and V1 receptors, respectively (96).
The sensitivity of the aldosterone effect to
spironolactone in the MDCK cell line would
indicate a genomic pathway. However, the
rapid nongenomic action of aldosterone on
H+-ATPase pump activity described in mouse
outer medullary collecting duct (OMCD)
intercalated cells was insensitive to inhibitors
of aldosterone interaction with MR and was
unaffected by inhibition of transcription and
translation (91). Both in amphibian skin and
in renal intercalated cells, the rapid actions of
aldosterone were prevented by incubation with
microtubule-disrupting agents and inhibitors
of PKC. The half-time for activation of H+
ﬂux and insertion of proton pumps into the
apical membranes of intercalated cells was
12min in the amphibian skin epithelium (94). A
threefold stimulation of H+ extrusion through
the vacuolar-type H+-ATPase pump was
detected within 15 min in mouse OMCD cells
(91). The rapidity of these responses precludes
a genomic pathway but does not rule out signal
transduction via MR. Rapid trafﬁcking of vac-
uolar H+-ATPase pump units into the luminal
membrane is a major regulatory mechanism
to enhance urinary acidiﬁcation in response
to elevated plasma pCO2 or luminal HCO3−
(97). A similar mechanism may explain the
rapid nongenomic stimulation of H+ extrusion
by aldosterone, but the details of the protein
kinase signaling network are still not worked
out and provide an exciting challenge for future
research. Apart from the lack of knowledge
about the physiological role of rapid actions of
aldosterone in regulating urinary acidiﬁcation,
little is known about the consequences of the
nongenomic responses on the latent genomic
effects of aldosterone.Moreover, little is known
of the contribution, if any, of dysregulation
of the early trafﬁcking effects induced by
aldosterone on proton pumps to disease states
that affect distal tubular acidosis and that result
from inborn errors of metabolism involving
vacuolar H+-ATPase subunits in the CCDs.
Another area of unexplored aldosterone
physiology is the functional interaction be-
tween acid-secreting intercalated cells and
Na+-absorbing principal cells. In amphibian
skin epithelium in vivo, when the luminal Na+
concentration is low (<10 mM), as is the case
in the distal tubule, proton secretion through
intercalated cells provides the transepithelial
charge compensation forNa+ absorption across
the principal cells (98). Under low externalNa+
conditions on the apical side of the epithelium,
Na+ uptake through principal cells is indirectly
electrically coupled toproton secretion through
intercalated cells. Therefore, aldosterone may
induce a simultaneous rapid nongenomic ef-
fect on both H+ secretion and Na+ absorption
in the CCD under physiological conditions of
low external NaCl. Testing the hypothesis that
aldosterone activation of electrogenic proton
ﬂux via H+-ATPase pumps in α-type interca-
lated cells energizes Na+ absorption through
ENaC in neighboring principal cells may re-
veal a novel physiological role for rapid nonge-
nomic effects of aldosterone in the CCD under
conditions of physiologically low luminal Na+
concentrations.
EGFR ACTIVATION VERSUS
EGFR TRANSACTIVATION
Epidermal growth factor (EGF) suppresses
Na+ transport in the CCD (99). EGF treat-
ment of isolated CHO cells heterologously ex-
pressing ENaC and EGFR resulted in a de-
crease in ENaC current, as measured in patch
clamp experiments, through the suppression
of channel open probability (100). This ef-
fect was detectable within 1 to 2 min of treat-
ment and was tyrosine kinase dependent but
did not involve direct tyrosine phosphoryla-
tion of ENaC subunits and was not blocked by
c-Src antagonism. Chronic treatment of renal
A6 cells with EGF or the more potent EGFR
ligand transforming growth factor α (TGFα)
also suppressed ENaC activity but through the
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downregulation of channel subunit mRNA
transcription, rather than through changes in
channel open probability (101). Acute treat-
ment of a conﬂuent A6 cell epithelium with
TGFα stimulated a rise in ENaC current,
which peaked within 15 min of treatment and
was attributed to a PI3K-dependent increase in
open probability (101). EGFR ligands can thus
stimulate or suppressENaCactivity, depending
on the experimental model employed and the
duration of exposure. EGFR is acutely transac-
tivated by aldosterone, but this transactivation
does involve receptor phosphorylationby c-Src,
which contributes to stimulating at least part of
the downstream repertoire of signaling events.
A couple of important questions are, How
does the activation of EGFR by EGF differ
from its transactivation by aldosterone, and
what are the signaling and physiological conse-
quences of this differential receptor activation?
EGFR has multiple amino acid residues that
can serve as targets for phosphorylation and
as sites of protein interaction for the recruit-
ment of speciﬁc signaling intermediates includ-
ing phospholipase Cγ (PLCγ), growth factor
receptor bound protein 2 (GRB2), cellular Ca-
sitas B-lineage lymphoma protein (c-Cbl), and
Src homology 2 domain–containing transform-
ing protein 1 (Shc1) (102). The EGFR phos-
phorylation state at these different sites may
vary according to the manner of activation,
and accessory signaling cascades are activated
in parallel with EGFR activation. Human epi-
dermal growth factor receptor 2 (HER2), rather
than EGFR, is the erythroblastic leukemia viral
oncogene B (ErbB) family member most highly
expressed in the CCD; this may differ from the
expression proﬁle in immortalized cell lines and
may contribute to the dichotomy inEGFeffects
found in different experimental models.
Na+/H+ EXCHANGER
REGULATION BY RAPID
ALDOSTERONE SIGNALING
The individual NHE isoforms have different
functions in the nephron. These functions are
reﬂected in their differential expression along
the segments of the nephron, their localization
in renal epithelial cells at their basolateral or
apical surfaces, and their distinct activation in
response to agonists. Acute and chronic treat-
ment with aldosterone has a pronounced ef-
fect on NHE activity in established renal cell
lines and in isolated nephron segments. How-
ever, publisheddata show somecontradiction in
terms of whether the effects are stimulatory or
inhibitory and which signal transduction cas-
cades are coupled to NHE modulation in the
different experimental models. The investiga-
tions do consistently show that the duration
of exposure to elevated aldosterone concentra-
tions is important in determining whether an
inhibitory effect or a stimulatory effect onNHE
activity is observed. Opposing effects of aldos-
terone on NHE activity may reﬂect the dif-
ferential expression of MR and GR along the
nephron with their differing afﬁnities for aldos-
terone as well as the coupling of NHE isoforms
to different signaling cascades and regulators in
different cell types. NHE can be directly phos-
phorylated to modify its activity, as can its ac-
cessory proteins, the NHE-regulatory factors
(NHERFs). NHE can be directly phosphory-
lated by ERK1/2, and the activation of NHE1
in CCD cells is ERK1/2 dependent (103). Sim-
ilarly, NHE activity can be linked to PKC acti-
vation through increases in [Ca2+]i (104, 105).
Nonelectrogenic Na+ transport in the
proximal renal tubule is subject to regulation
by aldosterone. NHE3 is the main transporter
facilitating Na+ reabsorption in the proximal
tubule, where >60% of the NaCl conservation
by the nephron occurs. NHE3 activity in hu-
man primary renal proximal tubule epithelial
cells (RPTECs) was sensitive to aldosterone
treatment over 72 h (106). However, MR
is expressed only at very low levels in the
proximal tubule, whereas GR is at much
higher abundance (19). In spite of this receptor
expression proﬁle, NaCl reabsorption by the
proximal tubule is spironolactone sensitive,
conﬁrming that aldosterone acts through MR
to promoteNHE3 activity (107). Furthermore,
aldosterone treatment of adrenalectomized
rats over ﬁve days did not promote an increase
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in total NHE3 abundance. Rather, aldosterone
treatment promoted the association of NHE3
with the apical brush border, suggesting either
the activation of subcellular vesicle trafﬁcking
to the cell membrane or the suppression of
NHE3 recycling from the membrane (108).
Aldosterone treatment of RPTEC cells for 72 h
maximally stimulated NHE3 activity at a 1-nM
concentration, whereas maximum expression
required the application of tenfold-higher
concentration of aldosterone. The action of
aldosterone on NHE3 activity at 100 nM
was entirely blocked by spironolactone, but
NHE3 surface expression was only partially
suppressed, raising the possibility that at this
high steroid concentration there may be some
GR involvement in NHE3 trafﬁcking. The
stimulation of NHE3 surface expression by
aldosterone was completely abolished by an-
tagonism of EGFR, and EGFR expression was
elevated in response to aldosterone treatment.
EGFR transactivation in some way contributed
to both the activation and the trafﬁcking of
NHE3, which was stimulated by aldosterone
in this experimental model. A similar biphasic
effect of aldosterone was observed in the colon,
where initial NHE3 membrane insertion was
the result of increased [Na+]i that resulted from
a PI3K-dependent rise in Na+/K+ pump activ-
ity. The second phase of NHE activation was
attributed to a SGK1-dependent rise in the ex-
pression of NHE3 and Na+/K+-ATPase (80).
Over a shorter time course of 15 to 20 min,
the nongenomic actions of aldosterone aug-
mented 1,25 dihydroxyvitamin D3 suppression
of NHE3 activity in the TAL through a mech-
anism that is ERK1/2 dependent but PI3K in-
dependent (109). The inhibition of exchanger
activity reduces the rate of apical HCO3− ab-
sorption, which is driven byH+ secretion. ERK
activation in response to α-adrenergic recep-
tor agonists promotes NHE3 activity, suggest-
ing that other signals distinguish the effects of
these ligands from the effects of aldosterone
(110). Nerve growth factor (NGF) also antag-
onizes NHE3 activity in the TAL (111) but
does so indirectly. Here ERK1/2 is also acti-
vated but in turn suppresses basolateral NHE1
activity, which indirectly inhibits apical NHE3.
Aldosterone infusion promotes a transient rise
in Na+ excretion from the kidneys of experi-
mental animals within 15 min of commence-
ment; this transient rise subsides when infusion
is stopped (112). This early phase of increased
Na+ excretion was not mirrored by a change in
HCO3−, K+, or Cl− excretion or a change in
urinary pH. The rapid activation of NHE3 in
the proximal nephron that precedes the later
stimulatory effects on ENaC in the ASDN and
on NHE3 may account for this effect of aldos-
terone onNa+ secretion. However, the physio-
logical usefulness of such activation in response
to a stimulus aimed at promoting Na+ conser-
vation is unclear. The [Na+] in the renal ul-
traﬁltrate reaching the CCD rises, resulting in
increased self-inhibition of ENaC and a shift in
the burden of Na+ reabsorption from the prox-
imal nephron to the distal nephron, where Na+
reabsorption is more tightly controlled by cor-
ticosteroids. There is thus a brief transient rise
in Na+ excretion as this physiological shift is
achieved.
Biphasic responses to aldosterone have also
been reported in the microdissected S3 (pars
recta) segment of the proximal tubule, which
displays concentration dependency and the
involvement of MR and GR as the signal-
initiating receptors (104). Aldosterone (1 pM)
stimulated an initial rise in [Ca2+]i within 1min,
followed 6 min later by a second increase
that was sustained for at least 1 h. This rise
in [Ca2+]i was mirrored by a stimulation of
NHE1-mediated pHi recovery rate under con-
ditions of acid loading, which was sensitive to
GR antagonism but not to MR antagonism.
This differs from the situation in mesenteric
blood vessels, where the aldosterone-induced
rise in [Ca2+]i and NHE1 activity was sensi-
tive to MR antagonism with eplerenone (105).
The responses in the S3 nephron segment af-
ter 1 h of aldosterone treatment were spirono-
lactone sensitive, indicating MR dependency,
and sensitive to inhibitors of transcription and
translation. The conclusion based on these data
is that GR is responsible for transducing an
early nongenomic [Ca2+]i signal, whereas the
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later phase of NHE1 stimulation depends on
changes in gene expression that are mediated
by MR. Treatment of the isolated S3 segments
with aldosterone at a supraphysiological con-
centration (1 μM) resulted in an ampliﬁedCa2+
response but a suppression of NHE activity to
less than basal levels rather than the stimulation
seen at lower concentrations.
Modulation of NHE activity by aldosterone
may also contribute to the activation of pH-
sensitive K+ATP channels in the basolateral
membrane to promote K+ recycling (113).
Other mechanisms for the regulation of api-
cal K+ channel activity rely upon elevated
SGK1 activity either to suppress Nedd4-2,
which ubiquitinates KCNQ2- and KCNQ3-
type K+ channels (114, 115), or to modulate
ROMK activity through direct phosphoryla-
tion of WNK4 by SGK1 (14). ROMK is the
principal K+-secreting channel in the kidney
and is expressed apically along theASDN (116).
Phosphorylation of ROMKby protein kinase A
(PKA) affects the pH sensitivity of the channel
(117) and also uncouples it fromCFTR, render-
ingROMKactivity insensitive to ATP.The dy-
namic interaction of ROMKwith CFTR is me-
diated by NHERF-2, which also binds SGK1
and PKA (118). It remains to be established
whether the rapid aldosterone-induced kinases
play a direct role in regulating ROMK activity.
ALDOSTERONE AND RENAL
CELL HYPERTROPHY
AND PROLIFERATION
Aldosterone stimulates a rapid rise in Na+/H+
exchange in renal CCD and MDCK cells. This
rise is due to an ERK1/2-dependent rise in
NHE1 activity (103, 119). The resulting tran-
sient rise in cytosolic pH may facilitate the
activation of pH-sensitive signaling interme-
diates that are involved in cell cycle progres-
sion, such as the ribosomal S6 kinase (RSK)
family protein kinases (120). This coupling of
ERK1/2 to cell cycle advancement through
NHE1 activation is also a facet of growth
factor–stimulated cell proliferation (121, 122).
Recent evidence points to aldosterone as a
regulator of cell growth and differentiation in
various tissues, including the nephron. Cir-
cumstantial evidence—e.g., the signaling cas-
cades that are sensitive to aldosterone treat-
ment, in particular the ERK1/2 MAP kinases,
PKCs, and the transactivation of growth factor
receptors—additionally indicates that aldos-
teronemay affect the growth of responsive cells.
The ERK1/2 signaling cascade is a key regu-
lator of many cellular processes in diverse tis-
sues, especially those linked to cell growth and
proliferation. The ERK1/2 cascade is rapidly
activated in response to aldosterone treatment
of cell line models for different segments of
the nephron, and this activation is generally
coupled to EGFR transactivation (123). Aldos-
terone also stimulates the expression of EGFR
in renal tubules of adrenalectomized rats, which
increases the EGF and TNFα sensitivity of
the renal cells and demonstrates the coupling
of corticosteroid and growth factor signaling.
SGK1 suppresses apoptosis-associated gene ex-
pression by phosphorylating and inhibiting
the forkhead box OA3 (FOXO3) transcription
factor (124).
Recently published data show that aldos-
terone affects the proliferation and differen-
tiation of isolated renal stem cells (125, 126)
as well as the proliferation of transformed
CCD cell lines (127). Evidence also points to
aldosterone involvement in the upregulation
of renin-secreting mesangial cell proliferation;
again a rapid increase in ERK1/2 activity is
implicated (128). There are, however, no ex-
perimental data from animal models indicat-
ing a role for aldosterone in initiating cell pro-
liferation in the adult, healthy distal nephron.
The situation in diseased kidneys may be differ-
ent. Dysregulation of epithelial cell prolifera-
tion is an important factor in chronic renal con-
ditions such as polycystic kidney disease (129),
which is a genetic disorder associated with mu-
tations in genes encoding polycystin I and poly-
cystin II (130, 131). However, hypertension is a
signiﬁcant factor contributing to cyst enlarge-
ment and the resulting decline in renal function.
EGFR expression is elevated in cells forming
these cysts (132). Transactivation of EGFR by
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aldosterone resulting in stimulation of ERK1/2
may be another factor inﬂuencing the rate of
disease progression and supports the rationale
for using MR antagonism at the earliest stages
of treatment (133).
CROSS-TALK BETWEEN
ALDOSTERONE-INDUCED
SIGNALING CASCADES AND
TRANSCRIPTION REGULATION
A key question is how rapidly induced signal
transduction cascades involving diverse inter-
mediates such as ERK1/2, PKC isoforms, and
Ca2+ mobilization, which are detectable within
a fewminutes, can impact major transcriptional
events such as SGK1 and ENaCα expression,
which occur much later (Figure 2). The an-
swer may be that the initiation of aldosterone-
induced gene expression is a synthesis of multi-
ple events that includeMRnuclear stabilization
and cofactor recruitment. The binding of MR
(and GR) by aldosterone directly affects gene
expression through the DNA-binding proper-
ties of these receptors and through the capac-
ity of the receptors to recruit coactivators and
corepressors to promoter sites in order to mod-
ulate transcription (134). MR resides in a mul-
tiprotein complex in the cytoplasm with part-
ners including Hsp90 (135). The displacement
of Hsp90 from this complex following aldos-
terone binding exposes a nuclear localization
signal on MR that promotes its translocation.
The induction of MR-dependent transcription
is sensitive to PKA antagonism with 8-bromo-
cAMP; a PKA-mediated phosphorylation event
may facilitate the release of MR from its cyto-
plasmic protein complex (136).
Nuclear receptors can also be phospho-
rylated. For example, estrogen receptor α
is phosphorylated on Ser118 by ERK1/2 in
breast carcinoma cells (137). This modiﬁcation
can promote ligand-independent nuclear
translocation of the receptor when malignant
cells switch from an endocrine-dependent
to a growth factor–dependent proliferative
phenotype. Similarly, MR also undergoes
phosphorylation in CCD cells following
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Figure 2
Aldosterone-induced signaling cascades modulate mineralocorticoid receptor
(MR)-dependent transcription. Aldosterone initiates the activation of signaling
cascades through interaction with MR or a membrane aldosterone receptor
(mAR). Activation of the adenylate cyclase (AC) protein kinase A (PKA) affects
nuclear translocation of cAMP-responsive element–binding protein (CREB)
and steroid receptor coactivators (SRC). Transactivation of epidermal growth
factor receptor (EGFR) or insulin-like growth factor receptor (IGFR) results in
the activation of the phosphoinositide 3-kinase (PI3K)-coupled protein kinases
phosphoinositide-dependent kinase (PDK) and Akt and activation of the novel
protein kinase C (nPKC)/protein kinase D (PKD) cascade, which in turn
stabilize extracellular stimulus–regulated kinase (ERK). ERK can
phosphorylate MR to promote its nuclear translocation and recruitment of the
transcription initiation mediator (MED) complex. Aldosterone-induced Ca2+
store depletion inﬂuences the trafﬁcking of macromolecular complexes through
nuclear pores (NP) to modulate gene expression.
aldosterone treatment, pointing to a coupling
of the early protein kinase signal transduction
cascades to the direct transcriptional effects
of aldosterone (82). The activation of p21-
activated kinase (PAK) through Rac1 small
GTPase stimulation augments the nuclear
translocation of MR and the induction of
transcription in response to aldosterone treat-
ment (49). It is not clear whether PAK directly
phosphorylates MR or whether its effects on
other signaling intermediates contribute to the
subcellular redistribution of MR. The protein
kinase cascades activated by aldosterone can
also impact transcription through the phospho-
rylation of (a) the cofactors that are recruited
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SRC: p160 steroid
receptor coactivator
by direct interaction with MR or (b) transcrip-
tion factors that modulate gene expression
independently of MR binding to DNA.
All steroid nuclear receptors require coac-
tivator transcription factors to promote gene
expression. Included among these transcrip-
tion factors are the p160 steroid receptor
coactivator (SRC) family of cofactors, which
form the core of the transcription preinitiation
protein complex, and the mediator (MED)
protein complex, which serves as the molec-
ular interface with RNA polymerase II. The
phosphorylation proﬁle of these coactivators
is determined by the intracellular signaling
environment, which in turn is inﬂuenced by dif-
ferent factors (including circulating steroids).
Consequently, the phosphorylation proﬁle
carries information about the environmental
stimuli to which cells are exposed. Coactivator
phosphorylation inﬂuences the speciﬁcity of
protein-protein interactions and determines
cofactor recruitment into the preinitiation
complex. Phosphorylation also determines
subcellular distribution and SRC sensitivity to
ubiquitination and degradation by the S20 pro-
teasome. The phosphorylation proﬁle of SRCs
in response to estrogen exposure in the context
of breast cancer is the best-studied model of
SRC posttranslational modiﬁcation. These co-
factors are required for aldosterone-dependent
transcription, and aldosterone-induced signal-
ing events also have the potential to inﬂuence
the phosphorylation of the SRCs and other
cofactors. Aldosterone-induced expression of
SGK1 and ENaCα requires the recruitment of
SRC1 to the promoter elements of these genes,
and SRC1 colocalizes with MR in the nuclei
of cells in the murine CCD (134). Each of the
coactivators has multiple phosphorylation sites
that are targeted by different kinases, and some
of these kinases are rapidly activated in response
to aldosterone treatment in the nephron. PKA
and p38 MAPK phosphorylate SRC2 and
SRC3, respectively, to affect ubiquitination
and stability (138, 139), whereas the recruit-
ment of MED1 into the mediator complex
requires phosphorylation by ERK1/2 (140).
The transient activation of cAMP signal-
ing by aldosterone was reported in CCD cells,
and PKA-dependent phosphorylation and ac-
tivation of the CREB transcription factor fol-
lowing aldosterone treatment were detected
(141). This has been proposed as the mecha-
nism underlying the MR-independent upreg-
ulation, following aldosterone treatment, of
gadd153 gene expression through activation of
its CRE/ATF promoter element (142). The in-
duction of gene expression by aldosterone was
antagonized with spironolactone or RU486 for
all but a small subset of aldosterone-responsive
genes that included gadd153. A number of re-
searchers have reported aldosterone-induced
PKA activation; however, investigators have
also described antagonism between the phys-
iological responses stimulated by forskolin and
aldosterone. More recent evidence points to
a suppression of CREB-dependent transcrip-
tion through the upregulation of protein phos-
phatase 2β (PP2B) activation by aldosterone
(143). This phenomenon may be due to the
speciﬁc activation of different subpopulations
and isoforms of adenylate cyclase and PKA by
forskolin and aldosterone; such activation may
lead to compartmentalized signaling within
cells. Alternatively, such suppression may re-
ﬂect a built-in negative feedback response that
is intrinsic to aldosterone signaling and that
makes cells refractive to further PKA stimula-
tion following the initial aldosterone-induced
response. The rapid activation of PP2B by al-
dosterone also emphasizes the need to under-
stand how signaling cascades are rapidly sup-
pressed by aldosterone, as well as the need to
determine the targets of aldosterone-induced
kinases.
The nuclear envelope forms an effective
barrier between cytosolic signaling events and
the genome. The nuclear pore complex (NPC)
gates the movement of macromolecules such as
transcription factors, kinases, and phosphatases
into the nucleus and transcribed mRNA into
the cytoplasm. The small size of the nuclear
pore means that the transport of macromolec-
ular complexes, millions of Daltons in size,
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requires dramatic changes in pore structure. Al-
dosterone treatment can modulate the chan-
nel dimensions of NPC to facilitate cytosol-
to-nucleus trafﬁcking and to increase nuclear
volume (144). The enhanced macromolecu-
lar transport detected in Xenopus laevis oocytes
following aldosterone treatment was transient,
lasting up to 15 min after hormone treat-
ment. This may represent a discrete time win-
dow when certain cytosol-to-nucleus trafﬁck-
ing events can occur (145). The structural
changes in the NPC are inﬂuenced by nuclear
Ca2+ store depletion (146) and ATP availabil-
ity (147), factors that the rapid actions of aldos-
terone may impact and that can consequently
affect the expression of genes independently of
direct MR-mediated transcription.
CONCLUSION
Many questions remain to be addressed con-
cerning the physiological importance of rapid
signaling events stimulated by aldosterone in
the renal tubule and at other aldosterone target
sites within the body. Points for consideration
include simultaneous stimulation of apparently
antagonistic signaling responses and discrep-
ancies between observations made in vivo
when compared with established renal cell line
models. An important consideration is that the
rapid responses to aldosterone are not neces-
sarily transduced to the same effectors as the
latent genomic effects. This raises the prospect
that at least some of these rapid effects poten-
tiate later events or impose an additional level
of regulation on aldosterone actions that are
dependent upon changes in gene transcription.
Rapidly activated signaling cascades couple the
activity of transport proteins at opposite poles
of the cell and may result in ﬁne adjustments
to physiological processes that can respond
more quickly to changes in circulatory aldos-
terone than to changes in protein expression
(Figure 1). Aldosterone-induced signaling
should not be thought of as a rapid response
from zero to a high physiological concentration
of hormone, which is often the approach used in
experimental models, but rather a continually
changing response to subtle changes in aldos-
terone secretion that is a reﬂection of the status
of electrolyte homeostasis within the body over
time. The secretion of corticosteroids was re-
garded as a smooth curve that reﬂected the stage
in the body’s diurnal cycle. It is now known that
in rodents, corticosterone is released according
to an ultradian rhythm: Brief peaks of varying
amplitude occur with a 50-min periodicity
throughout the diurnal cycle (148). This may
also be the case for aldosterone, for which
the amplitude of such peaks is determined
by physiological sensors affecting the RAAS.
The peaks in the ultradian rhythm of corti-
costerone release result in a pulsatory pattern
of GR-dependent transcription, with mRNA
abundance related to hormone concentration
(149). The interaction of steroid receptors with
their target DNA sequences is very transient
and, in synchronized cells, displays a very pre-
cise periodicity of receptor recycling between
the nucleus and cytoplasm (150). In this context
the cell is continually monitoring its external
environment for ﬂuctuations in steroid con-
centration. The differential rapid activation of
signaling cascades that determine the phospho-
rylation state of transcription factors can confer
a crucial level of sensitivity to the regulation
of aldosterone-dependent gene transcription
(Figure 2).
SUMMARY POINTS
1. Aldosterone induces the rapid nongenomic activation of signaling cascades in tissues that
express the mineralocorticoid receptor (MR), including the renal tubule.
2. Aldosterone-responsive signaling intermediatesmodulate the subcellular trafﬁcking, pro-
teolytic stability, and activation ofmembrane protein targets to regulate electrolyte trans-
port in synergy with the chronic genomic effects of aldosterone.
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3. The activation of protein kinases by aldosterone is coupled to transactivation of growth
factor receptors at the cell membrane, with implications for modulating cell growth.
4. Steroid hormones, including aldosterone, may enhance their own transcriptional re-
sponses through the phosphorylation of the nuclear steroid receptor and key transcrip-
tion factors, such as the steroid receptor coactivators.
5. Aldosterone-induced signaling cascades provide a mechanism for ﬁne-tuning the tran-
scriptional responses of the renal tubule cells by continually sensing the extracellular
endocrine environment.
FUTURE ISSUES
1. The nature of the receptor initiating rapid nongenomic aldosterone–induced signaling
remains to be clariﬁed. Data support the initiation from MR in most instances, but other
data support the existence of a plasma membrane–binding site for aldosterone.
2. The activation of apparently antagonistic signaling cascades by aldosterone may reﬂect
intrinsic negative feedback mechanisms or may be the result of localized sites of signal
activation leading to the activation of a very precise subset of molecular targets rather
than of all potential aldosterone targets within the cell.
3. The modulatory effect of the rapid signaling responses on the transcriptional effects of
MR is an emerging theme. The relevance of these events to the effects of aldosterone on
whole-body electrolyte and acid-base homeostasis remains to be understood.
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